Aug 19, 2026 · 6 min
Moderna surges as beauty beats and furniture falters
Moderna's Record Surge, Estee Lauder Rises on Q4 Beat, La-Z-Boy Sinks
The episode shows how sharply different trial results, earnings, and forecasts can redirect investor attention across sectors.
- 1Moderna shares posted a record 101% intraday surge after positive results for its personalized cancer vaccine developed with Merck.
- 2Estee Lauder rallied after a strong fourth-quarter performance and optimistic fiscal guidance.
- 3La-Z-Boy fell after reporting a quarterly loss and issuing a weak sales forecast.
Don't miss
Moderna shares surged a record 101% intraday after positive results for its personalized cancer vaccine developed with Merck.
The brief
Hosts Carol Massar and Alexis Christophorous frame a day of sharply divergent stock moves, with trial results, earnings, and forecasts pulling investors in opposite directions.
Moderna delivered the episode’s defining move: shares surged 101% intraday after positive results for a personalized cancer vaccine developed with Merck.
Estee Lauder offered a more conventional rally, as strong fourth-quarter earnings and optimistic fiscal guidance improved the outlook for the cosmetics company.
La-Z-Boy supplied the counterpoint, with a quarterly loss and weak sales forecast weighing on the furniture maker’s stock.
Together, the moves show why markets can reward promising clinical evidence and upbeat guidance while punishing a weaker forward sales picture.
What was said on this episode
14 statements · 9 positive · 4 negative · 1 neutral
Moderna stock rose more than 90% in premarket trading.
“the stock is nearly doubling here in the pre market is up more than 90%”
Listen at 1:04
Merck stock rose about 9%.
“Merck is up about 9%”
Listen at 1:09
The Moderna-Merck vaccine prevented cancer recurrence or spread in high-risk melanoma patients.
“it succeeded in preventing cancer from returning or spreading in high risk melanoma patients”
Listen at 1:17
Moderna hopes to launch the cancer vaccine next year.
“Moderna is hoping to have this cancer vaccine on the market next year”
Listen at 1:37
Moderna and Merck must prove the vaccine works in other tumor types.
“the companies will need to prove that the vaccine works in other tumor types too, not just melanoma”
Listen at 1:47
The cancer vaccine has substantial potential.
“But this is a huge potential here”
Listen at 1:52
Estée Lauder stock rose 12.5%.
“stock is up 12 and a half percent”
Listen at 2:14
Estée Lauder lost less money than analysts expected.
“They lost less money than expected last quarter”
Listen at 2:29
Estée Lauder’s turnaround is gaining momentum.
“Their turnaround is picking up. Steam”
Listen at 2:36
Estée Lauder guides for 3–5% organic net sales growth in the coming year.
“They're continuing to guide for organic net sales growth of 3 to 5% in the coming year”
Listen at 2:53
La-Z-Boy stock fell 17%.
“La Z Boy, the furniture company down 17%”
Listen at 3:08
La-Z-Boy sales fell 3%.
“Sales fell 3%”
Listen at 3:20
La-Z-Boy’s current-quarter sales forecast was below estimates.
“gave a sales forecast for the current quarter that was below estimates”
Listen at 3:23
La-Z-Boy’s near-term investments could pressure margins.
“its near term investments could pressure its margins”
Listen at 3:26
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
ChatGPT
The Estée Lauder Companies Inc.
La-Z-BoyListen to the full episode and explore every guest, topic, and moment on PodLume.